Actively Recruiting
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Led by Fujian Cancer Hospital · Updated on 2024-05-01
130
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1 Vs oxaliplatin plus S1.
CONDITIONS
Official Title
Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Histologically confirmed gastric adenocarcinoma with locally advanced cancer, tumor volume greater than 5 cm, Borrmann III, Borrmann IV, or Bulky N positive according to AJCC Version 8
- Measurable lesions detected by CT or MRI according to RECIST 1.1
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- No prior surgical treatment, chemotherapy, radiotherapy, or immunotherapy for gastric cancer
- Preoperative endoscopic exam showing no positive peritoneal implantation metastasis or exfoliated cells
- Expected survival time longer than 6 months
- Women of reproductive age must have a negative urine or serum pregnancy test within 3 days before first treatment; women are considered of childbearing age if at least 1 year post-menopause or have had surgical sterilization or hysterectomy
You will not qualify if you...
- Diagnosis of malignant diseases other than gastric cancer within 5 years before treatment, except certain skin cancers or carcinoma in situ
- Significant bleeding symptoms or bleeding tendency such as gastrointestinal bleeding or hemorrhagic gastric ulcer within 3 months before enrollment
- Positive fecal occult blood test at baseline confirmed by gastroscopy if reexamination remains positive
- Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2 drugs, or drugs targeting other T-cell receptors like CTLA-4, OX-40, CD137
- History of immunodeficiency including HIV positive status
- Participation in another interventional clinical study or use of another study drug or device within 4 weeks before initial dosing
- History of cardiovascular or cerebrovascular disease with ongoing oral thrombolytic or anticoagulant treatment
- Known HER2 positive status
- Previous gastrointestinal perforation, abdominal abscess, recent intestinal obstruction within 3 months, or clinical/imaging signs of intestinal obstruction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fujian cancer hospital
Fuzhou, Fujian, China, 350500
Actively Recruiting
Research Team
C
chen lu chuan, bachelor
CONTACT
Y
Ye Z sheng, Doctor of Medicine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here